-
News | 2022.12.07
SpikImm receives a major funding to accelerate the clinical and industrial development of its monoclonal antibodies against SARS-CoV-2
SpikImm, a biotech company founded in 2021 by Truffle Capital in collaboration with the Institut Pasteur, has been awarded a €15 million non-dilutive financing from the French governmentFrance 2030 program for its "PROPHYMAB" project, which is supported as part of the "Emerging Infectious Diseases and CBRN Threats" Acceleration Strategy. SPK001, the first treatment candidate (...
-
Document de presse | 2022.10.20
How SARS-CoV-2 communicates with human cells: mapping molecular contacts
Although the mechanisms by which SARS-CoV-2 enters host cells are increasingly well documented, the direct molecular interactions between virus and host remain poorly understood. Scientists from the Institut Pasteur, the French National Center for Scientific Research (CNRS), Université Paris Cité, the Institute of Network Biology (INET) Helmholtz Munich, the Donnelly Center for Cellular and...
-
News | 2022.12.05
Monnaie de Paris launches a Louis Pasteur commemorative coin
The Monnaie de Paris (Paris Mint) is celebrating the bicentenary of Louis Pasteur's birth by releasing a commemorative coin for sale bearing the scientist's image. For each coin sold, the Monnaie de Paris will donate €1 to the Institut Pasteur's research.
-
News | 2022.12.01
Institut Pasteur at the 2022 Utopiales international science fiction festival in Nantes
For the second year in a row, the Institut Pasteur was one of the official scientific partners of the Utopiales festival, which took place from October 29 to November 1 at La Cité Nantes Congress Center.
-
Portrait | 2022.12.13
Pierre-Marie Lledo: a neuro-optimist in work and in life
Perception, emotions, behavior, decision-making, memory, good mental health, depression – these are some of the research topics that interest Pierre-Marie Lledo. With his team of biologists, physicians, mathematicians, biophysicists and biochemists, he is working to uncover some of the most intimate mechanisms in the brain.
-
News | 2022.12.13
ERC Starting Grants: three scientists working at the Institut Pasteur among the successful candidates
On November 22, 2022, the European Research Council unveiled the list of recipients of ERC Starting Grants, a funding instrument aimed at early career scientists. The 408 laureates include three scientists working at the Institut Pasteur.
-
News | 2023.01.01
The Institut Pasteur wishes you a happy New Year
2023 will be marked by two major celebrations: the 40th anniversary of the discovery of HIV and the 20th anniversary of the discovery of the first genes involved in autism. Punctuated by these two major events, this new year will illustrate how the Pasteurian legacy is passed on from generation to generation and inspires today’s researchers.
-
News | 2023.01.02
Mitochondrial diseases: discovery of the role of a molecule essential to cardiac function
Scientists have identified the function of a protein that plays a key role in the structure and mechanisms of cardiac muscle. This molecule appears to be fundamental to the efficient supply of energy to cells. This is a major breakthrough in our understanding of the biological mechanisms involved in certain cardiac diseases.
-
Report | 2022.12.17
“Epidemics, pandemics, an endless story?”: a question for research, citizens and society
On Wednesday December 7, 2022, the Institut Pasteur hosted the conference Epidemics, pandemics: a never-ending story? Fifteen scientists and politicians spoke at the event, which was held in connection with the bicentenary of Louis Pasteur's birth. Here are some of the main conclusions to take away.
-
Document de presse | 2022.12.19
Modelling has evaluated the role of antiviral treatment and vaccination in exiting the Zero-COVID strategy in Wallis and Futuna
By June 2022, the Wallis and Futuna Islands, a French overseas territory, had successfully implemented a Zero-COVID strategy that significantly reduced the number of SARS-CoV-2 infections. From mid-June 2022, a gradual reopening of the borders was planned. However, the relatively low immunity in the population (due to limited vaccination coverage and the number of previous infections) and the...
